Literature DB >> 31409741

High FA2H and UGT8 transcript levels predict hydroxylated hexosylceramide accumulation in lung adenocarcinoma.

Anne-Marie Lemay1, Olivier Courtemanche1, Timothy A Couttas2,3, Giuleta Jamsari3, Andréanne Gagné1, Yohan Bossé1,4, Philippe Joubert1,5, Anthony S Don2,3,6, David Marsolais7,8.   

Abstract

Lung cancer causes more deaths than any other cancer. Sphingolipids encompass metabolically interconnected species whose balance has pivotal effects on proliferation, migration, and apoptosis. In this study, we paralleled quantification of sphingolipid species with quantitative (q)PCR analyses of metabolic enzymes in order to identify dysregulated routes of sphingolipid metabolism in different subtypes of lung cancers. Lung samples were submitted to histopathological reexamination in order to confirm cancer type/subtype, which included adenocarcinoma histological subtypes and squamous cell and neuroendocrine carcinomas. Compared with benign lesions and tumor-free parenchyma, all cancers featured decreased sphingosine-1-phosphate and SMs. qPCR analyses evidenced differential mechanisms leading to these alterations between cancer types, with neuroendocrine carcinomas upregulating SGPL1, but CERT1 being downregulated in adenocarcinomas and squamous cell carcinomas. 2-Hydroxyhexosylceramides (2-hydroxyHexCers) were specifically increased in adenocarcinomas. While UDP-glycosyltransferase 8 (UGT8) transcript levels were increased in all cancer subtypes, fatty acid 2-hydroxylase (FA2H) levels were higher in adenocarcinomas than in squamous and neuroendocrine carcinomas. As a whole, we report differing mechanisms through which all forms of lung cancer achieve low SM and lysosphingolipids. Our results also demonstrate that FA2H upregulation is required for the accumulation of 2-hydroxyHexCers in lung cancers featuring high levels of UGT8.
Copyright © 2019 Lemay et al.

Entities:  

Keywords:  2-hydroxyhexosylceramide; cancer; fatty acid 2-hydroxylase; fatty acids; gene expression; mass spectrometry; neuroendocrine; sphingolipid; squamous; uridine 5′-diphosphate-glycosyltransferase 8

Mesh:

Substances:

Year:  2019        PMID: 31409741      PMCID: PMC6795083          DOI: 10.1194/jlr.M093955

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  49 in total

1.  Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate.

Authors:  O Cuvillier; G Pirianov; B Kleuser; P G Vanek; O A Coso; S Gutkind; S Spiegel
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

2.  P-selectin mediates metastatic progression through binding to sulfatides on tumor cells.

Authors:  Josep Garcia; Nico Callewaert; Lubor Borsig
Journal:  Glycobiology       Date:  2006-10-16       Impact factor: 4.313

3.  Evidence Suggests Sphingosine 1-Phosphate Might Be Actively Generated, Degraded, and Transported to Extracellular Spaces With Increased S1P2 and S1P3 Expression in Colon Cancer.

Authors:  Baasanjav Uranbileg; Takeshi Nishikawa; Hitoshi Ikeda; Makoto Kurano; Masaya Sato; Daisuke Saigusa; Junken Aoki; Toshiaki Watanabe; Yutaka Yatomi
Journal:  Clin Colorectal Cancer       Date:  2017-11-21       Impact factor: 4.481

4.  SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway.

Authors:  Zhijing Zhao; Junfeng Ma; Baoquan Hu; Yi Zhang; Shushu Wang
Journal:  Exp Ther Med       Date:  2018-04-12       Impact factor: 2.447

5.  A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.

Authors:  Sumanta K Pal; Harry A Drabkin; James A Reeves; John D Hainsworth; Susan E Hazel; Dario A Paggiarino; Jon Wojciak; Gary Woodnutt; Rupal S Bhatt
Journal:  Cancer       Date:  2016-10-11       Impact factor: 6.860

Review 6.  Novel agents targeting bioactive sphingolipids for the treatment of cancer.

Authors:  A Adan-Gokbulut; M Kartal-Yandim; G Iskender; Y Baran
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

7.  Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases.

Authors:  P Dzięgiel; T Owczarek; E Plazuk; A Gomułkiewicz; M Majchrzak; M Podhorska-Okołów; K Driouch; R Lidereau; M Ugorski
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

8.  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

Authors:  Eugen Ruckhäberle; Achim Rody; Knut Engels; Regine Gaetje; Gunter von Minckwitz; Susanne Schiffmann; Sabine Grösch; Gerd Geisslinger; Uwe Holtrich; Thomas Karn; Manfred Kaufmann
Journal:  Breast Cancer Res Treat       Date:  2007-12-04       Impact factor: 4.872

9.  Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation.

Authors:  H Zhang; N N Desai; A Olivera; T Seki; G Brooker; S Spiegel
Journal:  J Cell Biol       Date:  1991-07       Impact factor: 10.539

10.  Galactosylceramide affects tumorigenic and metastatic properties of breast cancer cells as an anti-apoptotic molecule.

Authors:  Tomasz B Owczarek; Jarosław Suchanski; Bartosz Pula; Alicja M Kmiecik; Marek Chadalski; Aleksandra Jethon; Piotr Dziegiel; Maciej Ugorski
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

View more
  4 in total

1.  Dysregulated ceramides metabolism by fatty acid 2-hydroxylase exposes a metabolic vulnerability to target cancer metastasis.

Authors:  Xuantong Zhou; Furong Huang; Gang Ma; Wenqing Wei; Nan Wu; Zhihua Liu
Journal:  Signal Transduct Target Ther       Date:  2022-10-24

2.  A model of twenty-three metabolic-related genes predicting overall survival for lung adenocarcinoma.

Authors:  Zhenyu Zhao; Boxue He; Qidong Cai; Pengfei Zhang; Xiong Peng; Yuqian Zhang; Hui Xie; Xiang Wang
Journal:  PeerJ       Date:  2020-09-24       Impact factor: 2.984

3.  Altered Plasma, Urine, and Tissue Profiles of Sulfatides and Sphingomyelins in Patients with Renal Cell Carcinoma.

Authors:  Robert Jirásko; Jakub Idkowiak; Denise Wolrab; Aleš Kvasnička; David Friedecký; Krzysztof Polański; Hana Študentová; Vladimír Študent; Bohuslav Melichar; Michal Holčapek
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

Review 4.  Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression.

Authors:  Eric P Allain; Michèle Rouleau; Eric Lévesque; Chantal Guillemette
Journal:  Br J Cancer       Date:  2020-02-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.